Premature Ticagrelor Discontinuation in Secondary Prevention of Atherosclerotic CVD: JACC Review Topic of the Week | Journal of the American College of Cardiology
Adenosine-Mediated Effects of Ticagrelor: Evidence and Potential Clinical Relevance - ScienceDirect
Does prasugrel or ticagrelor suffice in patients with STEMI? | Nature Reviews Cardiology
JCM | Free Full-Text | New Antithrombotic Drugs in Acute Coronary Syndrome | HTML
Antiplatelet and Anticoagulation Therapy for Acute Coronary Syndromes | Circulation Research
Ticagrelor - Wikipedia
The Dogged Search for Cryptic Effects of Ticagrelor | Circulation
P2Y12 inhibitors
Update on novel P2Y12 inhibitors: Focus on Prasugrel, Ticagrelor, Cangrelor and Elinogrel
Rationale and design of PREvalence of DyspneA in patients treated with TicagrelOR (PREDATOR) program | Semantic Scholar
Ticagrelor mechanism of action | Pharmacology, Medical illustration, Medicine studies
Ticagrelor in ACS—what does PLATO teach us? | Nature Reviews Cardiology
New antiplatelet agents : ready for clinical application?
البورد العراقي للصيدلة السريرية - 🔺️P2Y12 receptor antagonists ➡️Ticlopidine, clopidogrel, prasugrel, ticagrelor and cangrelor are P2Y12 ADP receptor inhibitors that also block platelet aggregation but by a mechanism different from that of
Mechanisms underlying the probable adenosine-dependent and... | Download Scientific Diagram
Frontiers | Aspirin or Ticagrelor in Staphylococcus aureus Infective Endocarditis: Where Do We Stand? | Cell and Developmental Biology
Proposed Mechanism of... - Sultania Cardiovascular Sciences | Facebook
Ticagrelor for the treatment of atherosclerotic disease: insights from the PARTHENON clinical development program | Future Cardiology
How to manage prasugrel and ticagrelor in daily practice - European Journal of Internal Medicine
Ticagrelor: Positive, negative and misunderstood properties as a new antiplatelet agent - Steiner - 2013 - Clinical and Experimental Pharmacology and Physiology - Wiley Online Library
Ticagrelor: a cardiometabolic drug targeting erythrocyte-mediated purinergic signaling? | American Journal of Physiology-Heart and Circulatory Physiology
Ticagrelor: from discovery to Phase III clinical trial | Future Cardiology
Ticagrelor versus placebo for the reduction of vaso-occlusive crises in pediatric sickle cell disease: Rationale and design of a randomized, double-blind, parallel-group, multicenter phase 3 study (HESTIA3) - ScienceDirect
Mechanism of Action of Platelet Aggregation Inhibitors - ... | GrepMed
